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Abstract 
Background: Observational series suggest a mortality benefit from metformin in the heart failure (HF) population. 
However, the benefit of metformin in HF with preserved ejection fraction (HFpEF) has yet to be explored. We per-
formed a systematic review and meta-analysis to identify whether variation in EF impacts mortality outcomes in HF 
patients treated with metformin.
Methods: MEDLINE and EMBASE were searched up to October 2019. Observational studies and randomised trials 
reporting mortality in HF patients and the proportion of patients with an EF > 50% at baseline were included. Other 
baseline variables were used to assess for heterogeneity in treatment outcomes between groups. Regression models 
were used to determine the interaction between metformin and subgroups on mortality.
Results: Four studies reported the proportion of patients with a preserved EF and were analysed. Metformin reduced 
mortality in both preserved or reduced EF after adjustment with HF therapies such as angiotensin converting enzyme 
inhibitors (ACEi) and beta-blockers (β = − 0.2 [95% CI − 0.3 to − 0.1], p = 0.02). Significantly greater protective effects 
were seen with EF > 50% (p = 0.003). Metformin treatment with insulin, ACEi and beta-blocker therapy were also 
shown to have a reduction in mortality (insulin p = 0.002; ACEi p < 0.001; beta-blocker p = 0.017), whereas female 
gender was associated with worse outcomes (p < 0.001).
Conclusions: Metformin treatment is associated with a reduction in mortality in patients with HFpEF.
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Background
Heart failure (HF) with preserved ejection fraction 
(HFpEF) is a distinct phenotype hallmarked by clinical 
signs and symptoms of HF coupled with a normal ejec-
tion faction (EF ≥ 50%) and evidence of increased left 
ventricular (LV) pressures and impaired LV filling on 
echocardiography [1–3]. HFpEF accounts for almost 
half of the cases of HF and carries an equally poor prog-
nosis to those with HF with reduced ejection fraction 
(HFrEF), with an estimated 4-year mortality rate of 32% 
[4]. In contrast to HFrEF, where several therapies have 
shown good long-term morbidity and mortality out-
comes, despite multiple aetiologies leading to the same 
pathophysiological end-point [1–3, 5], effective therapy 
options for HFpEF have yet to be established. In part, this 
is because HFpEF is a heterogenous condition, with phe-
notypic clusters based on age, gender and comorbid ill-
nesses such as obesity, type 2 diabetes mellitus (T2DM) 
and hypertension [6, 7]. This ultimately leads to dysfunc-
tional metabolic pathways and mechanics within the 
myocardium resulting in the condition [6, 8]. Therefore, 
establishing therapy that targets these phenotypes may 
be the means by which HFpEF therapy evolves [6].
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Metformin is a common anti-diabetic drug with both 
systemic and cardioprotective benefits in addition to its 
hypoglycaemic effect [9, 10]. At the cellular level met-
formin activates adenosine monophosphate-activated 
protein kinase (AMPK) an important regulator of several 
metabolic pathways resulting in enhanced glucose utili-
sation, reduction of protein synthesis and improvement 
of mitochondrial function [11–13]. Furthermore, met-
formin has been shown to reduce collagen accumulation 
and potentially reduce LV hypertrophy and improve dias-
tolic function in the diabetic myocardium [14]. Several 
observational series have shown a reduction in mortal-
ity in the HF population [15, 16]. Its mortality benefit in 
the HFpEF population however has yet to be explored. 
We performed a systematic review and meta-regression 
analysis to identify whether variations in ejection fraction 
(EF) impact mortality outcomes in HF patients treated 
with metformin.
Methods
This systematic review was undertaken in accord-
ance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) statement [17]. 
The review was registered with the PROSPERO Inter-
national prospective register of systematic reviews (ID 
CRD42019133780) in September 2019.
Literature search
MEDLINE (1946 to October 2019) and EMBASE (1947 
to October 2019) electronic databases using  Ovid® were 
searched for randomised controlled trials and obser-
vational studies that assessed the impact of metformin 
therapy on mortality outcomes in adult HF patients (aged 
over 18  years). Common search terms included (‘heart 
failure’ or ‘cardiomyopathies’), (‘diastolic heart failure’ or 
‘preserved ejection fraction’), (‘metformin’ or ‘biguanide’) 
and (‘mortality’ or ‘death’). The full MEDLINE and 
EMBASE search strategies are detailed in the Additional 
file  1: Appendix S1. Reference mining of articles in the 
full-text review was undertaken as well as grey literature 
searching. Searches were restricted to human studies and 
those reported in the English language.
Study selection
Two reviewers (A.H. and J.S.) independently under-
took abstract screening and included studies reporting 
mortality outcomes in HF patients treated with met-
formin. Studies were divided as preserved or reduced EF; 
with the preserved group further subdivided into those 
that reported proportion of patients with EF ≥ 50% or 
EF ≥ 40%. and reported the proportion of patients with 
an EF ≥ 50%. Studies were excluded if [1] diagnosis of 
HF was based purely on hospital discharge codes and no 
information specifically pertaining to EF and mortality 
outcomes were recorded, and [2] quality of methodol-
ogy was not able to be critically appraised, for example 
in conference abstracts and unpublished studies. After 
exclusions based on title and abstract review, two inves-
tigators (A.H. and J.S.) independently undertook full 
text reviews for eligibility. Reference searching of review 
articles was undertaken to search for additional stud-
ies, however review articles were not formally included 
in the systematic review.  Covidence® (Melbourne, Aus-
tralia) software was used to track articles in the system-
atic review process. Conflicts were resolved by a third 
reviewer (T.H.M.).
Data extraction
Data extraction from eligible studies was undertaken 
independently by two researchers (A.H. and J.S.). Data 
was extracted on study design and characteristics, 
including year of publication, number of subjects, gen-
der, duration of follow-up, medical history (including his-
tory of coronary artery disease (CAD), hypertension and 
peripheral vascular disease (PVD)), baseline treatment 
with cardio-protective (angiotensin converting enzyme 
inhibitor (ACEi)/angiotensin receptor blocker (ARB), 
beta-blocker), and anti-diabetic medications (insulin and 
sulfonylurea therapy) and EF ≥ 50% on echocardiogra-
phy. Hazard ratios (HR) with associated 95% confidence 
intervals (95% CI) on mortality outcomes stratified by 
the presence or absence of metformin treatment were 
extracted.
Quality and risk of bias assessment
Quality and risk of bias was assessed using the Newcas-
tle–Ottawa quality assessment scale for cohort studies. 
This scale assesses the quality of a study based on patient 
selection, comparability and outcome. Included studies 
were ranked as good, fair or low quality as outlined in 
Additional file 1: Appendix S2.
Statistical analysis
Proportion of individuals within each subgroup are 
expressed as a percentage (%). The meta-analysis was 
performed using maximally adjusted HR and 95% CI 
to obtain an overall effect size using a random-effects 
model. Heterogeneity between studies was tested for 
mortality outcomes using the Chi square test with a p 
value < 0.05 being statistically significant. An  I2 statistic 
was generated with > 20% heterogeneity considered sig-
nificant. A sampling weight was assigned to adjust for dif-
ferences in study size contributions between each study 
by calculating the proportion of patients within each sub-
group based on the total number of individuals included 
in the final meta-analysis. Meta-regression models were 
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then performed to determine the interaction between the 
presence or absence of metformin therapy on mortality 
outcomes in each sub-group. All statistical analyses were 
performed using STATA software (StataCorp LLC 2019, 
v.16.0, College Station, TX, USA).
Results
Study selection
There were 836 studies identified in the search strat-
egy on mortality outcomes in HF patients treated with 
metformin, with 10 undergoing full-text review (Fig. 1). 
Of these, 4 reported the total proportion of patients at 
baseline with an EF ≥ 50% (Table 1) and were included 
in the final analysis [18–21]. Of the 6 studies excluded 
from the final analysis, 1 study excluded HF patients 
with an LVEF ≥ 40% [22] and 5 studies diagnosed HF at 
baseline based on hospital discharge diagnosis or Inter-
national Classification of Diseases (ICD) or Medicare 
codes and did not report EF data [23–27] as outlined in 
the Additional file 1: Appendix S2. 
Records identified through 
Medline and Embase 
database searching
n = 935
Additional records identified 
through reference mining or 
grey literature search 
n = 2
Records after duplicates 
removed
n = 836
Titles and abstracts 
screened
Records excluded
n = 800
Full text articles assessed 
for eligibility
n = 36
Full text articles excluded
n = 26
Reasons: 
- Review article = 10
- Abstract = 16
Studies reporting 
outcomes in patients with 
EF >40%
n = 4
Full text articles reporting 
mortality in heart failure 
population
n = 10
Fig. 1 Flow diagram showing literature search outcome and study selection
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Study characteristics
Study characteristics, baseline patient data and mortality 
outcomes are reported in Tables 1, 2 and 3. Populations 
studied were primarily in the United States of America 
and Spain. A total of 22, 469 individuals with HF were 
analysed with 7655 mortality events identified. Of the 
total number of individuals 10,168 (45%) had a preserved 
EF, however, one study reported the total proportion of 
participants with an EF ≥40% [18]. Follow-up ranged 
from 1 to 4.7 years. All studies used multiple covariates in 
adjustments of the effect size (Table 3) with two studies 
performing propensity matching in the analysis [18, 21]. 
Risk of bias and quality assessments
All studies included were observational, retrospective 
cohort studies (Table  1). Based on Newcastle–Ottawa 
quality assessment, all studies were deemed high quality 
(Additional file 1: Appendix S3).
Patient characteristics
Overall, patients in the metformin group tended to be 
younger than those in the non-metformin group (age 
71.2 ± 4 years vs. 73.3 ± 3 years, respectively; Table 2). In 
the metformin group, 1796 (39%) of patients were female, 
3499 (76%) were on an ACEi or ARB and 1351 (29%) were 
on insulin therapy. In contrast, in the non-metformin 
group 7890 (44%) were female, 11,546 (65%) were on an 
ACEi or ARB and 9762 (55%) were on insulin therapy.
Mortality outcomes
The pooled HR for mortality in all HF individuals treated 
with metformin therapy was 0.82 (95% CI 0.74, 0.90, 
p < 0.001; Fig.  2). The summary estimate demonstrated 
a moderate degree of heterogeneity between studies 
 (I2 = 58.0%, p < 0.001).
In the subgroup analysis (Table 4), metformin reduced 
mortality in both reduced and preserved EF after adjust-
ing for concurrent treatment with cardio-protective med-
ications, such as ACEi/ARB and beta-blocker therapy 
(β = − 0.2 [95% CI − 0.3, − 0.1], p = 0.02). After adjusting 
for the benefit of metformin in the EF ≥50% group irre-
spective of cardio-protective therapies, there was a sig-
nificantly greater reduction in mortality (β = − 2.3 [95% 
CI − 3.3, − 1.3], p = 0.003). In the reduced EF sub-anal-
ysis, metformin was not associated with a mortality ben-
efit (β = 0.2 [95% CI − 0.3, 0.6], p = 0.28). Furthermore, 
treatment with cardio-protective medications or insulin 
alone was associated with mortality reduction (ACEi/
ARB p < 0.001; beta-blocker p = 0.017; insulin p = 0.002). 
Interestingly, female gender was associated with worse 
outcomes (p < 0.001).
Discussion
This review demonstrates that metformin is associated 
with an 18% mortality reduction in all HF patients and 
that this benefit is observed in patients treated with con-
current cardio-protective medications, as seen in other 
clinical trials. However, this meta-analysis is the first to 
examine a mortality benefit of metformin therapy specifi-
cally in patients with a preserved EF.
Diabetic cardiomyopathy
T2DM is a complex metabolic disorder, with the initial 
hallmarks of insulin resistance and progressive impair-
ment in insulin secretion from the pancreas [28]. Over 
time a pro-inflammatory state develops, potentiated by 
Table 1 Characteristics of  included studies for  incident heart failure outcomes in  patients with  a  reported ejection 
fraction ≥ 50%
T2DM type 2 diabetes mellitus, HF heart failure, USA United States of America, LVEF left ventricular ejection fraction
a Study reported percentage of patients with LVEF≥ 40%
Study Year Country Design Population Sample Size Mean 
age 
(years)
Sex
(% females)
% of patients 
with LVEF ≥ 
50%
Follow-up 
(years)
Masoudi et al. [20] 2005 USA Observational, 
retrospective 
cohort
T2DM, 
age ≥ 65 years, 
hospitalisation 
with HF
13,930 76 58 23 1.0
Romero et al. [21] 2011 Spain Observational, pro-
spective cohort
New-onset T2DM, 
HF
1519 72 54 51 4.7
Facila et al.
[19]
2017 Spain Observational, 
retrospective 
cohort
T2DM, discharged 
with diagnosis of 
acute decom-
pensated HF
835 72 49 49 2.4
Aguilar et al. [18] 2011 USA Observational, 
retrospective 
cohort
T2DM, prior diag-
nosis of HF
6185 68 7 45a 2
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alterations in gut microbiota and excess adiposity [29]. 
Ultimately, end-organ failure ensues.
Diabetic cardiomyopathy is a major adverse outcome 
of the disease. Where the pathophysiology of DM and 
atherosclerotic CAD is well understood [30], there is an 
emergence of data on the cellular and metabolic mecha-
nisms of non-ischaemic driven diabetic cardiomyopathy. 
Alterations in the AMPK pathway and mitochondrial 
dysfunction are major components in the development of 
myocardial impairment [10].
Table 3 Development of HF in patients with and without preserved EF
HF heart failure, ECG electrocardiogram, eGFR estimated glomerular filtration rate, ACR albumin-creatinine ration, Hb haemoglobin, AHF acute heart failure, PVD 
peripheral vascular disease, HTN hypertension, LVEF left ventricular ejection fraction, NT pro-BNP N-terminal pro b-type natriuretic peptide, BMI body mass index, SBP 
systolic blood pressure, DBP diastolic blood pressure, CVD cerebrovascular disease, AF atrial fibrillation, MI myocardial infarction, COPD chronic obstructive pulmonary 
disease, ACEi angiotensin converting enzyme, ARB angiotensin receptor blocker
Study Treatment Total 
mortality 
events
Adjusted effect size [95% CI] Covariates in effect size adjustment
Masoudi et al. [20] Metformin vs. No Insulin sensitiser 4805 HR 0.86 [0.77, 0.97] Patient factors (such as age and gender), treat-
ing physician and hospital characteristics
Romero et al. [21] Metformin vs. No metformin 1045 HR 0.88 [0.83, 0.93] Propensity matched: age, gender, educational 
level, social situation, occupation situation, 
type of HF, aetiology of HF, clinical signs, radio-
logical data, ECG data, comorbidity, bloods 
(lipids, albumin, creatinine, eGFR, ACR, Hb, 
electrolyte levels), medication received, time 
to follow-up, place of diagnosis, income, early 
readmissions, time of hospitalisation, visits to 
medical professionals
Facila et al. [19] Metformin vs. No metformin 382 HR 0.68 [0.53, 0.87] Age, gender, prior admission for AHF, prior 
history of stroke, PVD, HTN, QRS > 120 ms, 
LVEF, eGFR, Hb, NT pro-BNP, treatment with 
beta-blockers
Aguilar et al. [18] Metformin vs. No Metformin 1423 HR 0.76 [0.63, 0.92] Propensity matched: Age, gender, race, BMI, SBP, 
DBP, LVEF, history of hypertension, PVD, CVD, 
AF, MI, cancer, COPD and diabetic complica-
tions, HF hospitalisation within the last 2 years, 
bloods (Hb, HbA1c, sodium, urea, eGFR, total 
cholesterol and triglycerides) and treatment 
with beta-blockers, sulfonylurea, thiazolidin-
ediones, insulin, statins, ACEi/ARB
Fig. 2 Meta-analysis of effect estimates for mortality in heart failure patients treated with and metformin therapy
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Metformin systemic and myocardial mechanism of action
Metformin is the most commonly prescribed anti-dia-
betic drug [31]. It has negligible hypoglycaemic risk, has 
beneficial effects on HbA1c and weight reduction and is 
relatively inexpensive [31]. In recent years its position in 
guideline-directed management of new-onset T2DM has 
somewhat changed. The American Diabetes Association 
still recommends metformin as first-line therapy in all 
newly diagnosed T2DM patients [31]; however, the Euro-
pean Society of Cardiology now recommends metformin 
as first-line therapy only in patients who are deemed not 
at high-risk or do not have established cardiovascular dis-
ease, instead recommending a sodium glucose cotrans-
porter-2 inhibitor (SGLT-2i) or glucagon-like protein-1 
receptor agonist (GLP-1 RA) for these patients [32].
In recent years our understanding of metformin’s 
mechanism of action has evolved. At the cellular level, 
metformin accumulates in the mitochondrial matrix ulti-
mately causing a reduction in the synthesis of adenosine 
triphosphate (ATP) and an increase in the level of AMP 
resulting in the activation of the AMPK pathway [10]. 
In the liver, decreased ATP availability and inhibition of 
enzymes involved in lactate uptake results in inhibition 
of gluconeogenesis [9, 10, 33, 34]. Additionally, by acti-
vating AMPK metformin modifies lipid production and 
breakdown [10, 34]. In the intestinal tract, metformin 
inhibits glucose absorption and improves insulin pro-
duction by the incretin affect [35]. In adipocyte tissue 
metformin reduces free-fatty acid release [36], further 
improving glucose uptake in other tissues such as skeletal 
muscle [37].
In the myocardium, metformin also activates AMPK 
resulting in increased glucose uptake, reduction in pro-
tein synthesis and improved mitochondrial function [10]. 
Furthermore, metformin decreases nitric oxide (NO) 
production via inhibition of inducible NO synthetase 
(iNOS) [12]. Finally, metformin has been shown to 
reduce collagen synthesis and fibrosis in myocardial tis-
sue [14].
Metformin in T2DM and cardiovascular disease
In the UK Prospective Diabetes Study, obese DM-indi-
viduals treated with metformin had a 42% (p = 0.017) 
risk reduction in diabetes-related deaths and a 36% 
(p = 0.011) reduction in all-cause mortality [38]. Further-
more, there was a 30% (p = 0.020) reduction of all macro-
vascular complications (MI, sudden death, angina, stroke 
and PVD) with metformin treatment [38].
The benefit of metformin therapy has been observed 
across multiple cardiovascular subgroups. In patients 
with established CAD, metformin was associated with a 
29% reduction in cardiovascular mortality (HR 0.81 [95% 
CI 0.79, 0.84], p < 0.001) and a 33% reduction in all-cause 
mortality (HR 0.67 [95% CI 0.60, 0.75], p < 0.001) [39]. 
Furthermore, in a propensity-matched study of patients 
followed up after an acute coronary syndrome (ACS), 
metformin was associated with a 50% reduction (HR 
0.50 [95% CI 0.26, 0.95], p = 0.035) in all-cause mortal-
ity [40]. However, in an analysis of patients treated with 
metformin presenting with their first ACS, metformin 
was associated with increased MACE (HR 1.13 [95% CI 
1.03, 1.23], p = 0.006) but in those patients who survived 
beyond 30-days after the index event, metformin was 
not associated with MACE (HR 1.06 [95% CI 0.95, 1.17, 
p = 0.305) [41].
In heart transplant recipients, cardiac allograft vascu-
lopathy (CAV) is a major cause of morbidity and mortal-
ity with limited treatment options [42]. However, in heart 
Table 4 Interaction between metformin and subgroups on mortality outcomes
CI confidence interval, LVEF left ventricular ejection fraction, CAD coronary artery disease, PVD peripheral vascular disease, ACEi angiotensin converting enzyme 
inhibitor, ARB angiotensin receptor blocker
Subgroups β-coefficient for the interaction with metformin 
and mortality [95% CI]
P-value R-squared
Female Gender 4.9 [3.7–6.1] < 0.001 0.993
LVEF≥50% − 2.3 [− 3.3, − 1.3] 0.003 0.954
LVEF < 50% 0.2 [− 0.2, 0.6] 0.279 0.863
CAD − 2.0 [− 10.3, 6.2] 0.530 0.801
PVD − 3.4 [− 4.4, − 2.3] 0.001 0.969
Hypertension − 1.4 [− 2.8, 0.1] 0.060 0.909
ACEi/ARB − 1.1 [− 1.3, − 0.8] < 0.001 0.974
Beta blocker − 1.6 [− 2.7, − 0.5] 0.017 0.934
Insulin − 1.8 [− 2.5, − 1.0] 0.002 0.958
Sulfonylurea 2.7 [− 0.5, 5.9] 0.077 0.915
Metformin treatment adjusted for LVEF, ACEi/ARB and 
beta-blocker therapy
− 0.2 [− 0.3, − 0.1] 0.020 0.996
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transplant patients treated with metformin prior to the 
development of CAV, metformin therapy was associated 
a 90% risk reduction in the development of CAV over a 
20-year follow-up period (HR 0.1 [0.02, 0.46], p = 0.003) 
[42]. Furthermore, metformin was independently asso-
ciated with a 91% reduction (p = 0.003) in the combined 
end-point of CAV and cardiovascular mortality in these 
patients [42].
Metformin in HF
Historically, the use of metformin has been restricted in 
HF owing to concerns regarding the development of life-
threatening lactic acidosis [43]. This adverse side-effect 
was largely extrapolated from data regarding phenformin, 
a biguanide that was ultimately withdrawn from the mar-
ket [43]. However, the development of metformin-associ-
ated lactic acidosis in HF patients has since been refuted. 
In a large observational study spanning over 10  years, 
27% of HF patients were on metformin therapy and there 
were no observed hospitalisations or deaths due to lactic 
acidosis [23].
Nonetheless, several observational studies have shown 
both morbidity and mortality benefits of HF patients 
treated with metformin. In a previous meta-analysis, 
metformin in HF patients was associated with a 7% 
reduction in HF hospitalisations (adjusted RR 0.93 [95% 
CI 0.86, 0.98], p = 0.01) and a 20% reduction in all-cause 
mortality (RR 0.80 [95% CI 0.74, 0.87], p < 0.001) [16]. 
Furthermore, this benefit extends to subgroups of HF 
such that in patients with CAD, all-cause mortality was 
reduced by 16% (HR 0.84 [0.81, 0.87], p = 0.03) [39]. In 
patients with hypertension, long-term metformin treat-
ment was associated with a reduction in LV filling pres-
sures and LV mass over-time [44]. In these patients the 
incidence of symptomatic HFpEF was also reduced with 
metformin therapy compared to non-metformin therapy 
(4.6% vs. 11.9% respectively, p = 0.020) [44]. The results 
of the current meta-analysis supporting these findings 
in the HF population with an 18% reduction in mortal-
ity associated with metformin therapy. Furthermore, this 
meta-analysis has shown a mortality benefit associated 
with metformin in patients with HFpEF. This is of clinical 
relevance as there are limited therapeutic options with 
mortality benefits in this population of HF patients.
Limitations
Despite a thorough literature search, there is a potential 
risk of not identifying all studies that have evaluated met-
formin use in HF patients, particularly those that were 
performed as a sub-group analysis. However, our use of 
reference mining and grey-literature searches are likely 
to have minimised this. Furthermore, due to the nature 
of observational studies, unaccounted confounding 
variables may have influenced individual study results. 
No randomised control trial of the use of metformin in 
HF patients exists and so this issue cannot be mitigated. 
The use of aggregate data rather than individual patient 
data may have limited the analysis.
Finally, our analysis was limited to observational stud-
ies of metformin in all HF patients, rather than HFpEF as 
a single entity. Due to the lack of reporting of outcomes 
in HFpEF patients our analysis was limited to a meta-
regression in this sub-group. Furthermore, due to the low 
number of studies included we encountered a significant 
amount of heterogeneity, ultimately reflecting the paucity 
of evidence in this area and the requirement for further 
research.
Conclusions
This meta-analysis is the first to highlight a mortality 
benefit for metformin therapy in HF patients with a pre-
served EF.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 3-020-01100 -w.
 Additional file 1: Appendix S1. Search terms. Appendix S2. Studies 
that underwent full-text review and were excluded from the final analysis. 
Appendix S3. Quality assessment using the Newcastle-Ottawa quality 
assessment scale. * indicates the study has met the criteria.
Abbreviations
ACEi: Angiotensin converting enzyme inhibitors; AMP: Adenosine monophos-
phate; AMPK: Adenosine monophosphate-activated protein kinase; ARB: Angi-
otensin receptor blocker; ATP: Adenosine triphosphate; CAD: Coronary artery 
disease; CAV: Cardiac allograph vasculopathy; EF: Ejection fraction; GLP-1 RA: 
Glucagon like protein-1 receptor agonist; HR: Hazard ratios; HF: Heart failure; 
HFpEF: HF with preserved ejection fraction; HFrEF: HF with reduced ejection 
fraction; ICD: International Classification of Diseases; iNOS: Inducible nitric 
oxide synthetase; LV: left ventricular; MACE: Major adverse cardiovascular 
events; NO: Nitric oxide; PRISMA: Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis; PVD: Peripheral vascular disease; SGLT-2i: Sodium 
glucose cotransporter-2 inhibitor; T2DM: Type 2 diabetes mellitus.
Acknowledgements
The authors would like to thank the staff at the Ian Potter Library (Alfred 
Hospital, Melbourne, Australia) for their assistance with the systematic review. 
Professor Marwick is the guarantor for this paper and takes full responsibility 
for the work as a whole, including the study design, access to data, and the 
decision to submit and publish the manuscript.
Authors’ contributions
AH performed the search, gathered the data and wrote the 1st draft, JS 
assisted with gathering data, QH assisted with the analysis and interpreta-
tion, THM supervised the project and was a major contributor in writing the 
manuscript. All authors read and approved the final manuscript.
 Availability of data and materials
Made on request to the authors.
Ethics approval and consent to participate
Not applicable (systematic review and meta-analysis).
Page 9 of 10Halabi et al. Cardiovasc Diabetol          (2020) 19:124  
Consent for publication
Not applicable (systematic review and meta-analysis).
Competing interests and funding
None.
Author details
1 (Dept) Imaging Research, Baker Heart and Diabetes Institute, PO Box 6492, 
75 Commercial Road, Melbourne, VIC 3004, Australia. 2 School of Public Health 
and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, 
VIC 3004, Australia. 3 (Dept) Imaging Research, Menzies Institute for Medical 
Research, 17 Liverpool Street, Hobart, TAS 7000, Australia. 4 Faculty of Medi-
cine, Dentistry and Health Sciences, The University of Melbourne, 207 Bouverie 
Street, Parkville, VIC 3010, Australia. 
Received: 28 April 2020   Accepted: 25 July 2020
References
 1. Group NCHFGW, Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, 
MacDonald PS, et al. National Heart Foundation of Australia and Cardiac 
Society of Australia and New Zealand: guidelines for the prevention, 
detection, and management of heart failure in Australia 2018. Heart Lung 
Circ. 2018;27(10):1123–208.
 2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, 
et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and 
chronic heart failure: the Task Force for the diagnosis and treatment of 
acute and chronic heart failure of the European Society of Cardiology 
(ESC)Developed with the special contribution of the Heart Failure Asso-
ciation (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
 3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 
2013 ACCF/AHA guideline for the management of heart failure: executive 
summary: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on practice guidelines. Circulation. 
2013;128(16):1810–52.
 4. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. 
The prognostic significance of heart failure with preserved left ventricular 
ejection fraction: a literature-based meta-analysis. Eur J Heart Fail. 
2009;11(9):855–62.
 5. Bolam H, Morton G, Kalra PR. Drug therapies in chronic heart failure: a 
focus on reduced ejection fraction. Clin Med (Lond). 2018;18(2):138–45.
 6. Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with 
preserved ejection fraction. Heart Fail Clin. 2014;10(3):407–18.
 7. Xanthopoulos A, Triposkiadis F, Starling RC. Heart failure with preserved 
ejection fraction: classification based upon phenotype is essential for 
diagnosis and treatment. Trends Cardiovasc Med. 2018;28(6):392–400.
 8. Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure 
with preserved ejection fraction: a review of cardiac and noncardiac 
pathophysiology. Front Physiol. 2019;10:638.
 9. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. 
Diabetologia. 2017;60(9):1577–85.
 10. Dziubak A, Wojcicka G, Wojtak A, Beltowski J. Metabolic effects of met-
formin in the failing heart. Int J Mol Sci. 2018;19(10):2869–91.
 11. Bertero E, Maack C. Calcium signaling and reactive oxygen species in 
mitochondria. Circ Res. 2018;122(10):1460–78.
 12. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-
activated protein kinase inhibits protein synthesis associated with 
hypertrophy in the cardiac myocyte. J Biol Chem. 2004;279(31):32771–9.
 13. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. 
Metformin prevents progression of heart failure in dogs: role of AMP-
activated protein kinase. Circulation. 2009;119(19):2568–77.
 14. Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ. Effects of 
metformin on collagen glycation and diastolic dysfunction in diabetic 
myocardium. J Cardiovasc Pharmacol Ther. 1998;3(4):319–26.
 15. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock 
CK, et al. Clinical outcomes of metformin use in populations with chronic 
kidney disease, congestive heart failure, or chronic liver disease: a system-
atic review. Ann Intern Med. 2017;166(3):191–200.
 16. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjos-
vold L, et al. Comparative safety and effectiveness of metformin in 
patients with diabetes mellitus and heart failure: systematic review 
of observational studies involving 34,000 patients. Circ Heart Fail. 
2013;6(3):395–402.
 17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. 
Ann Intern Med. 2009;151(4):264–9, W64.
 18. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use 
and mortality in ambulatory patients with diabetes and heart failure. 
Circ Heart Fail. 2011;4(1):53–8.
 19. Facila L, Fabregat-Andres O, Bertomeu V, Navarro JP, Minana G, Garcia-
Blas S, et al. Metformin and risk of long-term mortality following an 
admission for acute heart failure. J Cardiovasc Med (Hagerstown). 
2017;18(2):69–73.
 20. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz 
HM. Thiazolidinediones, metformin, and outcomes in older patients 
with diabetes and heart failure: an observational study. Circulation. 
2005;111(5):583–90.
 21. Romero SP, Andrey JL, Garcia-Egido A, Escobar MA, Perez V, Corzo R, et al. 
Metformin therapy and prognosis of patients with heart failure and new-
onset diabetes mellitus. A propensity-matched study in the community. 
Int J Cardiol. 2013;166(2):404–12.
 22. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes 
in patients with advanced systolic heart failure and diabetes. J Card Fail. 
2010;16(3):200–6.
 23. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen 
CH, et al. Metformin treatment is associated with a low risk of mortality 
in diabetic patients with heart failure: a retrospective nationwide cohort 
study. Diabetologia. 2010;53(12):2546–53.
 24. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved 
clinical outcomes associated with metformin in patients with diabetes 
and heart failure. Diabetes Care. 2005;28(10):2345–51.
 25. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, et al. 
Effect of Metformin on mortality in patients with heart failure and type 2 
diabetes mellitus. Am J Cardiol. 2010;106(7):1006–10.
 26. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund 
PS, et al. Treatment of type 2 diabetes and outcomes in patients with 
heart failure: a nested case-control study from the U.K. General Practice 
Research Database. Diabetes Care. 2010;33(6):1213–8.
 27. Retwinski A, Kosmalski M, Crespo-Leiro M, Maggioni A, Opolski G, Pon-
ikowski P, et al. The influence of metformin and the presence of type 2 
diabetes mellitus on mortality and hospitalisation in patients with heart 
failure. Kardiol Pol. 2018;76(9):1336–43.
 28. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn 
CR. Role of glucose and insulin resistance in development of type 
2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 
1992;340(8825):925–9.
 29. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, 
Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: 
current concepts and future perspectives. Eur Cardiol. 2019;14(1):50–9.
 30. Chiha M, Njeim M, Chedrawy EG. Diabetes and coronary heart disease: a 
risk factor for the global epidemic. Int J Hypertens. 2012;2012:697240.
 31. American Diabetes A. 9. Pharmacologic approaches to glycemic 
treatment: standards of medical care in diabetes-2019. Diabetes Care. 
2019;42(Suppl 1):S90–102.
 32. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, 
et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovas-
cular diseases developed in collaboration with the EASD. Eur Heart J. 
2020;41(2):255–323.
 33. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, 
et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial 
glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6.
 34. Zheng J, Woo SL, Hu X, Botchlett R, Chen L, Huo Y, et al. Metformin 
and metabolic diseases: a focus on hepatic aspects. Front Med. 
2015;9(2):173–86.
 35. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal 
tract. Diabetologia. 2016;59(3):426–35.
 36. Castro Cabezas M, van Wijk JP, Elte JW, Klop B. Effects of metformin on 
the regulation of free Fatty acids in insulin resistance: a double-blind, 
placebo-controlled study. J Nutr Metab. 2012;2012:394623.
Page 10 of 10Halabi et al. Cardiovasc Diabetol          (2020) 19:124 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 37. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of met-
formin on insulin-stimulated glucose transport in isolated skeletal muscle 
obtained from patients with NIDDM. Diabetologia. 1994;37(8):826–32.
 38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-
glucose control with metformin on complications in overweight patients 
with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) 
Group. Lancet. 1998;352(9131):854–65.
 39. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause 
and cardiovascular mortality in patients with coronary artery diseases: a 
systematic review and an updated meta-analysis. Cardiovasc Diabetol. 
2019;18(1):96.
 40. Jong CB, Chen KY, Hsieh MY, Su FY, Wu CC, Voon WC, et al. Metformin 
was associated with lower all-cause mortality in type 2 diabetes with 
acute coronary syndrome: a Nationwide registry with propensity score-
matched analysis. Int J Cardiol. 2019;291:152–7.
 41. Bromage DI, Godec TR, Pujades-Rodriguez M, Gonzalez-Izquierdo A, 
Denaxas S, Hemingway H, et al. Metformin use and cardiovascular 
outcomes after acute myocardial infarction in patients with type 2 diabe-
tes: a cohort study. Cardiovasc Diabetol. 2019;18(1):168.
 42. Ram E, Lavee J, Tenenbaum A, Klempfner R, Fisman EZ, Maor E, et al. 
Metformin therapy in patients with diabetes mellitus is associated with 
a reduced risk of vasculopathy and cardiovascular mortality after heart 
transplantation. Cardiovasc Diabetol. 2019;18(1):118.
 43. Kuan W, Beavers CJ, Guglin ME. Still sour about lactic acidosis years later: 
role of metformin in heart failure. Heart Fail Rev. 2018;23(3):347–53.
 44. Gu J, Yin ZF, Zhang JF, Wang CQ. Association between long-term prescrip-
tion of metformin and the progression of heart failure with preserved 
ejection fraction in patients with type 2 diabetes mellitus and hyperten-
sion. Int J Cardiol. 2020;306:140–5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
